Sanofi India is currently trading at Rs. 2199.00, up by 7.40 points or 0.34% from its previous closing of Rs. 2191.60 on the BSE.
The scrip opened at Rs. 2191.00 and has touched a high and low of Rs. 2206.30 and Rs. 2173.55 respectively. So far 9 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2429.95 on 02-Jan-2012 and a 52 week low of Rs. 2002.10 on 07-Jun-2012.
Last one week high and low of the scrip stood at Rs. 2,299.95 and Rs. 2173.55 respectively. The current market cap of the company is Rs. 5064.43 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 27.61% and 12.00% respectively.
Sanofi India sees potentials in animal health business in India and plans to enter the market with products from Merial, its global animal health arm. The company will launch these products for cattle, small animals, poultry, veterinary medicines, vaccines and products for companion animals or pets.
The company’s entry into the animal health segment comes even as other majors such as Bayer and Boehringer Ingelheim step up their play in the segment. The company expects growth in sectors like dairy, poultry, sheep and companion animal segments to grow, as domestic animal health market is growing at 8-11%.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1667.70 |
| Dr. Reddys Lab | 1221.45 |
| Cipla | 1239.95 |
| Zydus Lifesciences | 932.80 |
| Lupin | 2310.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: